Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
March 25, 2021 at 08:00 am EDT
Share
Mayinglong Pharmaceutical Group Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 2,791.591 million compared to CNY 2,705.396 million a year ago. Operating income was CNY 500.470 million compared to CNY 424.599 million a year ago. Net income was CNY 419.058 million compared to CNY 359.967 million a year ago. Basic earnings per share from continuing operations was CNY 0.97 compared to CNY 0.84 a year ago.
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. 
